HC Wainwright Has Pessimistic View of Kamada FY2024 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of Kamada in a research note issued on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $0.25 per share for the year, down from their prior estimate of $0.28. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.24 per share.

Separately, StockNews.com lowered shares of Kamada from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 27th.

Kamada Stock Up 2.4 %

KMDA stock opened at $5.95 on Monday. Kamada has a twelve month low of $4.60 and a twelve month high of $6.53. The firm has a market capitalization of $342.01 million, a PE ratio of 21.25 and a beta of 1.05. The stock has a 50-day simple moving average of $5.49 and a two-hundred day simple moving average of $5.47.

Institutional Investors Weigh In On Kamada

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares during the last quarter. Y.D. More Investments Ltd boosted its position in shares of Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after acquiring an additional 690,842 shares during the last quarter. Plato Investment Management Ltd purchased a new position in shares of Kamada during the third quarter worth about $117,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Kamada in the third quarter worth approximately $77,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.